The use of targeted therapies and selection of the optimal treatment sequence in heterogeneous population of patients with metastatic kidney cancer. Results of retrospective study

Renal cancer is one of the most rapidly spreading diseases in the world. As you know, a few years ago, overall survival of patients with metastatic renal cell carcinoma (mRCC) was disappointing: median overall survival rarely exceeded 13 months, while 5-year survival rate was less than 5 %. Immunoth...

Full description

Saved in:
Bibliographic Details
Main Authors: P. S. Borisov, M. I. Shkol’nik, R. V. Orlova, P. A. Karlov
Format: Artigo
Language:Russo
Published: ABV-press 2016-09-01
Series:Onkourologiâ
Subjects:
metastatic renal cell cancer
targeted medications
progression-free survival
overall survival
Online Access:https://oncourology.abvpress.ru/oncur/article/view/608
Tags: Add Tag
No Tags, Be the first to tag this record!
Loading...

Similar Items